The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: An investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 687-696

  Vermeersch, Kristina ^a   Gabrovska, Maria ^b   Deslypere, Griet ^c   Demedts, Ingel K ^d   Slabbynck, Hans ^d   Aumann, Joseph ^c   Ninane, Vincent ^b   Verleden, Geert M ^a   Troosters, Thierry ^a   Bogaerts, Kris ^e,f   Brusselle, Guy G ^g   Janssens, Wim ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c Jessa Ziekenhuis   (Belgium)

^d Department of Respiratory Medicine ^*  (Belgium)

^e KU LEUVEN   (Belgium)

^f HASSELT UNIVERSITY   (Belgium)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute exacerbation; Azithromycin; COPD; Macrolide antibiotics; Physical activity; RCT

Indexed keywords

AZITHROMYCIN; PLACEBO; ANTIINFECTIVE AGENT;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACOECONOMICS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE; ACUTE DISEASE; CLINICAL TRIAL; DISEASE COURSE; HOSPITALIZATION; METHODOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HOSPITALIZATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN;

EID: 84962408723     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S95501     Document Type: Article

References (42)

1. Celli BR, Decramer M, Wedzicha JA, et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir Rev. 2015; 24: 159-172.
2. Dewar M, Curry RW Jr. Chronic obstructive pulmonary disease: diagnostic considerations. Am Fam Physician. 2006; 73: 669-676.
3. Janssens W, Lehouck A, Decramer M, et al. Vitamin D and the Lung: Mechanisms and Disease Associations. Massachusetts: Springer; 2012: 239-260.
4. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187: 347-365.
5. Decramer M, De BF, Del PA, et al. Systemic effects of COPD. Respir Med. 2005; 99(suppl B): S3-S10.
6. Laveneziana P, Palange P. Physical activity, nutritional status and systemic inflammation in COPD. Eur Respir J. 2012; 40: 522-529.
7. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011; 378: 1015-1026.
8. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370: 786-796.
9. Wilson R, Sethi S, Anzueto A, et al. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect. 2013; 67: 497-515.
10. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157: 1418-1422.
11. Wilson R, Anzueto A, Miravitlles M, et al. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J Chron Obstruct Pulmon Dis. 2011; 6: 373-383.
12. Donath E, Chaudhry A, Hernandez-Aya LF, et al. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir Med. 2013; 107: 1385-1392.
13. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361: 449-456.
14. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359: 1543-1554.
15. Criner GJ, Bourbeau J, Diekemper RL, et al. Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015; 147: 883-893.
16. Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, et al. European COPD audit: design, organisation of work and methodology. Eur Respir J. 2013; 41: 270-276.
17. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008; 359: 2355-2365.
18. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67: 957-963.
19. Coeman M, van DY, Bauters F, et al. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. Ther Adv Respir Dis. 2011; 5: 377-386.
20. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998; 157: 1829-1832.
21. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290: 1749-1756.
22. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011; 37: 164-172.
23. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380: 660-667.
24. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365: 689-698.
25. Wenzel RP, Fowler AA 3rd, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med. 2012; 367: 340-347.
26. Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013; 107: 637-648.
27. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J. 2013; 42: 239-251.
28. Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008; 46: 1157-1164.
29. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med. 2006; 354: 1589-1600.
30. Global strategy for the diagnosis, management, and prevention of COPD: updated 2015. Global Initiative for Chronic Obstructive Lung Disease; 2015. Available from: http: //www. goldcopd. org/guidelines-global-strategy-for-diagnosis-management. html. Accessed August 31, 2015.
31. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013; 309: 2223-2231.
32. Walters JA, Wang W, Morley C, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011; 10: CD006897.
33. Cheng T, Gong Y, Guo Y, et al. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials. Clin Respir J. 2013; 7: 305-318.
34. Shepard RM, Falkner FC. Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother. 1990; 25(suppl A): 49-60.
35. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990; 25(suppl A): 73-82.
36. Vos R, Vanaudenaerde BM, Verleden SE, et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation. 2012; 94: 101-109.
37. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999; 340: 1941-1947.
38. Van RH, Raste Y, Louvaris Z, et al. Validity of six activity monitors in chronic obstructive pulmonary disease: a comparison with indirect calorimetry. PLoS One. 2012; 7: e39198.
39. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2012; 156: 105-114.
40. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012; 40: 17-27.
41. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994; 13: 1341-1352.
42. Bauer P, Rohmel J, Maurer W, et al. Testing strategies in multi-dose experiments including active control. Stat Med. 1998; 17: 2133-2146.